Smith & Nephew (NYSE:SNN) won a nod from the FDA for its Pico negative-pressure wound therapy system.
The British orthopedics giant’s wound care division said the FDA cleared the device for use in the home and in hospitals. It’s already on the market in Europe, Canada and Australia, according to a press release.
"The Pico system is indicated for chronic, acute and traumatic wounds, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts, and closed surgical incisions," according to the release. "For the payer, the Pico system is more affordable than traditional NPWT, and can significantly reduce therapy costs associated with traditional NPWT. The Pico system is available off-the-shelf and therefore may reduce the occurrence of delayed hospital discharges."
"We are the first company to deliver effective, single use, disposable NPWT using the combination of a small, portable pump and advanced dressing technology," added SNN’s North American advanced wound management president Thomas Dugan. "The Pico system demonstrates our commitment to innovation and reinforces our pledge to help reduce the human and economic cost of wounds."
Check out this video of the device:
More regulatory news from MassDevice.com:
Stanmore Implants wins 510(k) for juvenile tumor system
Stanmore Implants received 510k clearance for its juvenile tumor system, a non-invasive extendible distal femoral replacement for use in pediatric orthopedic oncology surgeries. Read more
Avedro lands CE Mark for Lasik Xtra
Avedro’s Lasik Xtra procedure won CE Mark approval in the European Union. The 2-minute procedure is used in conjunction with standard Lasik treatment to restore the biomechanical integrity and strength to the cornea. Read more
Mirador Biomedical wins expanded Compass clearance
Mirador Biomedical won FDA clearance to market its Compass digital pressure-sensing medical device for a new set of indications, according to Xconomy. Read more
PLC Systems advances push for RenalGuard approval in Japan
PLC Systems (OTC:PLCSF) is one step closer to having its RenalGuard system approved in Japan, after a cardiologist there used the device in a pair of procedures to prevent contrast-induced nephropathy. Read more